Multiple Myeloma Clinical Trial

A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

Summary

The main aims of this 3-part study are as follows:

Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that does not cause harmful side effects is found.

Part 2: To assess clinical activity of one or more dosing schedules of modakafusp alfa alone in participants with relapsed/refractory multiple myeloma. Dexamethasone standard dose will be administered with one or more selected dose of modakafusp alfa in selected group of participants.

Part 3: To find the optimal dose with the more favorable risk-benefit profile of modakafusp alfa.

Participants will receive modakafusp alfa at one of two doses which will be given through a vein.

View Full Description

Full Description

The drug being tested in this study, and which will be given through a vein, is called modakafusp alfa (TAK-573 ) as single agent or in combination with dexamethasone. The study will determine the safety, tolerability, and efficacy of modakafusp alfa as single agent and in combination with dexamethasone in participants with relapsed/refractory multiple myeloma (RRMM). The study consists of 3 Parts:

Part 1: Dose Escalation, Part 2: Dose Expansion, Part 3: Dose Extension

The study will enroll approximately 65 participants in Part 1, 35 in Part 2, and 236 in Part 3. Participants will be assigned to one of the following treatment groups in Parts 1 and 2 of the study. Participants will be randomly assigned in Part 3 of the study as given below:

Part 1 (Dose Escalation) Schedule A: Modakafusp alfa 0.001 Up to 14 mg/kg
Part 1 (Dose Escalation) Schedule B: Modakafusp alfa TBD
Part 1 (Dose Escalation) Schedule C: Modakafusp alfa TBD
Part 1 (Dose Escalation) Schedule D: Modakafusp alfa TBD
Part 2 (Dose Expansion): Modakafusp alfa TBD + Dexamethasone 40 mg
Part 3 (Dose Extension): Modakafusp alfa 120 mg
Part 3 (Dose Extension): Modakafusp alfa 240 mg

The Part 1 (Dose Escalation) portion of the study will follow a 3+3 dose escalation design to evaluate once-weekly up to 4 different schedules of administration of modakafusp alfa starting at 0.001 mg/kg for dose limiting toxicity (DLT) evaluation and to determine the maximum tolerated dose (MTD) or an optimal biological dose (OBD) for assessments in Part 2.

The Part 2 (Dose Expansion) will further assess the safety profile of modakafusp alfa and its efficacy at MTD or OBD.

For Part 3 (Dose Extension) participants will be randomized 1:1 to receive single-agent modakafusp alfa 120 mg or 240 mg Q4W.

Parts 1 and 2 will be conducted at multiple centers in the United States. Part 3 will be conducted worldwide. The maximum treatment duration in this study is up to 12 months (Parts 1 and 2) or until disease progression (Part 3) and overall time to participate in the study is approximately up to 90 months. Participants with clinical benefit may continue treatment after sponsor approval.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

For Parts 1 and 2:

1. Has MM defined by the IMWG criteria with evidence of disease progression and:

In need of additional myeloma therapy as determined by the investigator.
Has previously received at least 3 lines of myeloma therapy (for example, containing an Immunomodulatory imide drug [IMiD], a proteasome inhibitor [PI], an alkylating agent, and/or an anti-CD38 as single agents or in combination).
Is either refractory to or intolerant of at least 1 PI and a least 1 IMiD.

For Part 3:

Has MM defined by the IMWG criteria with evidence of disease progression and:

In need of additional myeloma therapy as determined by the investigator.
Has previously received at least 3 lines of myeloma therapy.
Is refractory to at least 1 IMiD (ie, lenalidomide or pomalidomide [thalidomide excluded]), at least 1 PI (ie, bortezomib, ixazomib, or carfilzomib), and refractory to at least 1 anti-CD38 antibody (ie, daratumumab or isatuximab) and has demonstrated disease progression with the last therapy. Participants who are primary refractory, meaning they never achieved at least a MR with any previous treatment line, are not eligible.

For participants in Part 2 and 3 only: Measurable disease is defined as :

Serum M-protein ≥500 mg/dL (≥5 g/L)
Urine M-protein ≥200 mg/24 hours.
Serum free light chain (FLC) assay, with involved FLC level ≥10 mg/dL (≥100 mg/L) provided serum FLC ratio is abnormal.
During Part 1 only, participants not meeting the above criteria for measurable disease should, at least, have measurable bone marrow plasmacytosis (greater than or equal to [≥ ] 10 percent [%]) and/or plasmacytoma (≥1 centimeter [cm] in diameter) detected by physical examination or imaging.
Eastern Cooperative Oncology Group (ECOG) performance status of ≤2.

Exclusion Criteria:

For Parts 1 and 2:

Has polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes (POEMS) syndrome, monoclonal gammopathy of unknown significance, smoldering myeloma, solitary plasmacytoma, amyloidosis, Waldenstrom macroglobulinemia or immunoglobulin M (IgM) myeloma, or lymphoplasmacytic lymphoma (LPL).
Who have received autologous stem cell transplant (SCT) 60 days before first infusion of modakafusp alfa or participants who have received allogeneic SCT 6 months before first infusion. Graft-versus-host disease that is active or requires ongoing systemic immunosuppression.
Has not recovered from adverse reactions to prior myeloma treatment or procedures (chemotherapy, immunotherapy, radiation therapy) to NCI CTCAE less than or equal to (≤) Grade 1 or baseline, except for sensory or motor neuropathy which should have recovered to ≤ Grade 2 or baseline.
Has clinical signs of central nervous system involvement of MM.

For Part 3:

Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection. Seropositive for hepatitis B (defined by a positive test for hepatitis B surface antigen [HBsAg]. Participants with resolved infection (that is, participants who are HBsAg negative but positive for antibodies to hepatitis B core antigen [anti-HBc] and/or antibodies to hepatitis B surface antigen [anti-HBs]) must be screened using real-time polymerase chain reaction (PCR) measurement of HBV DNA levels. Those who are PCR positive will be excluded.
In addition to the above criteria, participants must not have plasma cell leukemia or have had primary refractory MM, current central nervous system involvement of MM, myelodysplastic syndrome, myeloproliferative syndrome, or have had a second malignancy within the previous 3 years, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, cervical carcinoma in situ, resected colorectal adenomatous polyps, breast cancer in situ, or other malignancy for which the participant is not on active anticancer therapy.

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

336

Study ID:

NCT03215030

Recruitment Status:

Recruiting

Sponsor:

Takeda

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 109 Locations for this study

See Locations Near You

Highlands Oncology Group
Springdale Arkansas, 72762, United States More Info
Site Contact
Contact
479-936-9901
[email protected]
Patrick Travis
Principal Investigator
Los Angeles Cancer Network - Glendale Adventist Medical Center
Glendale California, 91204, United States More Info
Site Contact
Contact
818-303-3150
[email protected]
Lasika Seneviratne
Principal Investigator
University of California Irvine
Orange California, 92868, United States More Info
Site Contact
Contact
714-456-5153
[email protected]
Lisa Lee
Principal Investigator
Office of James R. Berenson MD
West Hollywood California, 90069, United States More Info
Site Contact
Contact
310-623-1222
[email protected]
James Berenson
Principal Investigator
Smilow Cancer Hospital at Yale New Haven
New Haven Connecticut, 06520, United States More Info
Site Contact
Contact
203-833-2701
[email protected]
Terri Parker
Principal Investigator
Winship Cancer Institute of Emory University
Atlanta Georgia, 30322, United States More Info
Site Contact
Contact
404-778-4322
[email protected]
Jonathan Kaufman
Principal Investigator
Northwestern Medicine - Northwestern Medical Group
Chicago Illinois, 60611, United States More Info
Site Contact
Contact
312-695-4159
[email protected]
Seema Singhal
Principal Investigator
Loyola University Medical Center
Maywood Illinois, 60153, United States More Info
Site Contact
Contact
708-327-3142
[email protected]
Patrick Hagen
Principal Investigator
Johns Hopkins Hospital
Baltimore Maryland, 21287, United States More Info
Site Contact
Contact
410-955-4042
[email protected]
Christian Gocke
Principal Investigator
Boston Medical Center
Boston Massachusetts, 02118, United States More Info
Site Contact
Contact
857-250-6914
[email protected]
Raphael Szalat
Principal Investigator
Dana Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Site Contact
Contact
617-632-4952
[email protected]
Omar Nadeem
Principal Investigator
Univeristy of Nebraska Medical Center
Omaha Nebraska, 68198, United States More Info
Site Contact
Contact
402-559-8500
[email protected]
Sarah Holstein
Principal Investigator
USOR - Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas Nevada, 89119, United States More Info
Site Contact
Contact
702-952-3400
[email protected]
Edwin Kingsley
Principal Investigator
John Theurer Cancer Center
Hackensack New Jersey, 07601, United States More Info
Site Contact
Contact
551-996-5234
[email protected]
Noa Biran
Principal Investigator
Montefiore Medical Center
Bronx New York, 10467, United States More Info
Site Contact
Contact
718-920-4321
[email protected]
Nishi Shah
Principal Investigator
University of Rochester
Rochester New York, 14627, United States More Info
Site Contact
Contact
913-588-5059
[email protected]
Brea Lipe
Principal Investigator
Levine Cancer Center
Charlotte North Carolina, 28402, United States More Info
Site Contact
Contact
704-774-9322
[email protected]
Shebli Atrash
Principal Investigator
Levine Cancer Institute - Concord
Concord North Carolina, 28205, United States More Info
Site Contact
Contact
704-774-9322
[email protected]
Shebli Atrash
Principal Investigator
Duke University Medical Center
Durham North Carolina, 27710, United States More Info
Site Contact
Contact
919-668-2331
[email protected]
Yubin Kang
Principal Investigator
Gabrail Cancer Center
Canton Ohio, 44718, United States More Info
Site Contact
Contact
330-492-3345
[email protected]
Nashat Gabrail
Principal Investigator
The Ohio State University
Columbus Ohio, 43210, United States More Info
Site Contact
Contact
614-293-7638
[email protected]
Srinivas Devarakonda
Principal Investigator
Oregon Health and Science University
Portland Oregon, 97239, United States More Info
Site Contact
Contact
503-494-5304
[email protected]
Rebecca Silbermann
Principal Investigator
Penn State Hershey Cancer Institute
Hershey Pennsylvania, 17033, United States More Info
Site Contact
Contact
408-605-5806
[email protected]
Seema Naik
Principal Investigator
University of Pennsylvania
Philadelphia Pennsylvania, 19104, United States More Info
Site Contact
Contact
215-615-6508
[email protected]
Dan Vogl
Principal Investigator
Baptist Cancer Center - Memphis - Walnut Grove
Memphis Tennessee, 38120, United States More Info
Site Contact
Contact
901-752-6131
[email protected]
Muhammed Raza
Principal Investigator
Lumi Research
Houston Texas, 77002, United States More Info
Site Contact
Contact
281-319-8380
[email protected]
Saleha Sajid
Principal Investigator
Huntsman Cancer Institute
Salt Lake City Utah, 84112, United States More Info
Site Contact
Contact
612-624-0123
[email protected]
Brian McClune
Principal Investigator
British Columbia Cancer Agency Vancouver Centre
Vancouver British Columbia, V5Z 4, Canada More Info
Site Contact
Contact
1 (604) 877-6000
[email protected]
Christopher Venner
Principal Investigator
Juravinski Cancer Centre
Hamilton Ontario, L8V 5, Canada More Info
Site Contact
Contact
1 (905) 387-9495
[email protected]
Hira Mian
Principal Investigator
Victoria Hospital
London Ontario, N6A 4, Canada More Info
Site Contact
Contact
519-682-8500
[email protected]
Martha Louzada
Principal Investigator
Centre de Recherche du CHUM
Montreal Quebec, H2X 0, Canada More Info
Site Contact
Contact
1 (514) 890-8000
[email protected]
Emilie Lemieux-Blanchard
Principal Investigator
Sir Mortimer B. Davis Jewish General Hospital
Montreal Quebec, H3T 1, Canada More Info
Site Contact
Contact
1 (514) 340-8222
[email protected]
Rayan Kaedbey
Principal Investigator
Beijing Chao-Yang Hospital
Beijing Beijing, 10002, China More Info
Site Contact
Contact
+8601085231000
[email protected]
Wenming Chen
Principal Investigator
Beijing Chao-Yang Hospital
Beijing Beijing, 10004, China More Info
Site Contact
Contact
+8618600405718
[email protected]
Zhongxia Huang
Principal Investigator
Peking University People's Hospital
Beijing Beijing, 10004, China More Info
Site Contact
Contact
+8613311491805
[email protected]
Jin Lu
Principal Investigator
Peking University Third Hospital
Beijing Beijing, 10008, China More Info
Site Contact
Contact
+861068964010
[email protected]
Hongmei Jing
Principal Investigator
Sun Yat-Sen University Cancer Center
Guangzhou Guangdong, 51006, China More Info
Site Contact
Contact
+8613602713223
[email protected]
Zhongjun Xia
Principal Investigator
Henan Cancer Hospital
Zhengzhou Henan, 45000, China More Info
Site Contact
Contact
+8613526607830
[email protected]
Baijun Fang
Principal Investigator
Wuhan Union Hospital
Wuhan Hubei, 43002, China More Info
Site Contact
Contact
+8615342346782
[email protected]
Chunyan Sun
Principal Investigator
Zhongnan Hospital of Wuhan University
Wuhan Hubei, 43007, China More Info
Site Contact
Contact
+8602767812888
[email protected]
Fuling Zhou
Principal Investigator
Nanjing Drum Tower Hospital
Nanjing Jiangsu, 21000, China More Info
Site Contact
Contact
+862583105860
[email protected]
Bing Chen
Principal Investigator
The First Affiliated Hospital of Soochow University - Suzhou First People's Hospital
Suzhou Jiangsu, 21500, China More Info
Site Contact
Contact
+8613962191404
[email protected]
Zhenzhen Fu
Principal Investigator
Tianjin Medical University Cancer Institute & Hospital
Tianjin Tianjin, 30006, China More Info
Site Contact
Contact
+8618622221250
[email protected]
Yefei Wang
Principal Investigator
The First Affiliated Hospital, Zhejiang University
Hangzhou Zhejiang, 31000, China More Info
Site Contact
Contact
+8613857190311
[email protected]
Zhen Cai
Principal Investigator
Fakultni Nemocnice Olomouc
Olomouc Severomoravsky KRAJ, 775 2, Czechia More Info
Site Contact
Contact
+420588445351
[email protected]
Jiri Minarik
Principal Investigator
Fakultni Nemocnice Brno
Brno , 625 0, Czechia More Info
Site Contact
Contact
+420532233645
[email protected]
Ludek Pour
Principal Investigator
Univerzita Karlova - 1. Lekarska Fakulta
Praha , 128 0, Czechia More Info
Site Contact
Contact
+420224962527
[email protected]
Ivan Spicka
Principal Investigator
Institut de cancerologie Strasbourg Europe
Strasbourg Alsace, 67200, France More Info
Site Contact
Contact
+33368677301
[email protected]
Cecile Sonntag
Principal Investigator
Centre Hospitalier Universitaire Henri Mondor
Creteil Cedex Ile-de-france, 91010, France More Info
Site Contact
Contact
+33149814963
[email protected]
Karim Belhadj-Merzoug
Principal Investigator
Hopital Saint-Antoine
Paris Cedex 12 Ile-de-france, 75012, France More Info
Site Contact
Contact
+33149282162
[email protected]
Mohamad Mohty
Principal Investigator
Hopital Necker-Enfants Malades
Paris Ile-de-france, 75015, France More Info
Site Contact
Contact
33144495292
[email protected]
Laurent Frenzel
Principal Investigator
Centre Hospitalier Universitaire de Toulouse Hopital Purpan
Toulouse Midi-pyrenees, 31059, France More Info
Site Contact
Contact
+33383153282
[email protected]
Aurore Perrot
Principal Investigator
Hopital Saint-Vincent de Paul - Lille
Lille Cedex NORD Pas-de-calais, 59020, France More Info
Site Contact
Contact
+33320874532
[email protected]
Emmanuelle Bourgeois
Principal Investigator
Centre Hospitalier Regional Universitaire de Lille
Lille Cedex NORD Pas-de-calais, 59037, France More Info
Site Contact
Contact
+33320445713
[email protected]
Salomon Manier
Principal Investigator
Centre Hospitalier Universitaire Nantes - Hotel Dieu
Nantes Cedex 1 PAYS DE LA Loire, 44093, France More Info
Site Contact
Contact
+33253482405
[email protected]
Cyrille Touzeau
Principal Investigator
Centre Hospitalier Universitaire de Poitiers
Poitiers Poitou-charentes, 86000, France More Info
Site Contact
Contact
+33549444201
[email protected]
Xavier Leleu
Principal Investigator
Universitatsklinik Tubingen
Tuebingen Baden-wuerttemberg, 72076, Germany More Info
Site Contact
Contact
+4970712982711
[email protected]
Britta Besemer
Principal Investigator
Universitatsklinikum Dusseldorf
Duesseldorf Nordrhein-westfalen, 40225, Germany More Info
Site Contact
Contact
+492118100
[email protected]
Amelie Boquoi
Principal Investigator
Universitatsklinikum Leipzig
Leipzig Sachsen, 04103, Germany More Info
Site Contact
Contact
+49034197109
[email protected]
Maximilian Merz
Principal Investigator
Universitatsklinikum Hamburg-Eppendorf
Hamburg , 20251, Germany More Info
Site Contact
Contact
+4940741058581
[email protected]
Katja Weisel
Principal Investigator
Evaggelismos General Hospital
Athens Attica, 10676, Greece More Info
Site Contact
Contact
+302132041725
[email protected]
Sosana Delimpasi
Principal Investigator
Alexandra General Hospital of Athens
Athens Attica, 11528, Greece More Info
Site Contact
Contact
+302132162541
[email protected]
Meletios Dimopoulos
Principal Investigator
University Regional General Hospital of Patras
Patra Peloponnese, 26504, Greece More Info
Site Contact
Contact
+302613603255
[email protected]
Argiris Symeonidis
Principal Investigator
Cork University Hospital
Cork , T12 D, Ireland More Info
Site Contact
Contact
+3530214922000
[email protected]
Vitaliy Mykytiv
Principal Investigator
Saint Vincent's University Hospital
Dublin , D04 T, Ireland More Info
Site Contact
Contact
+35312774000
[email protected]
Kamal Fadalla
Principal Investigator
Mater Misericordiae University Hospital
Dublin , D07 R, Ireland More Info
Site Contact
Contact
+353018500977
[email protected]
Peter O'Gorman
Principal Investigator
National University of Ireland Galway
Galway , H91 T, Ireland More Info
Site Contact
Contact
353-91-492184
[email protected]
Janusz Krawczyk
Principal Investigator
The Chaim Sheba Medical Center
Ramat Gan Tel Aviv, 52621, Israel More Info
Site Contact
Contact
050-406-5462
[email protected]
Hila Magen
Principal Investigator
Hadassah Medical Center
Jerusalem , 91120, Israel More Info
Site Contact
Contact
+97226776685
[email protected]
Moshe Gatt
Principal Investigator
Tel Aviv Sourasky Medical Center
Tel Aviv , 64239, Israel More Info
Site Contact
Contact
+97236972521
[email protected]
Yael Cohen
Principal Investigator
AON SS Antonio e Biagio e Cesare Arrigo
Alessandria , 15121, Italy More Info
Site Contact
Contact
+39 0131 206072
[email protected]
Federico Monaco
Principal Investigator
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
Ancona , 60126, Italy More Info
Site Contact
Contact
+390715964235
[email protected]
Massimo Offidani
Principal Investigator
Azienda Ospedaliero-Universitaria di Bologna - Policlinico Sant'Orsola-Malpighi
Bologna , 40138, Italy More Info
Site Contact
Contact
+390516363111
[email protected]
Michele Cavo
Principal Investigator
Azienda Ospedaliero - Universitaria Policlinico - Vittorio Emanuele
Catania , 95125, Italy More Info
Site Contact
Contact
+390957431111
[email protected]
Francesco Di Raimondo
Principal Investigator
Department of Medicine (DIMED) Hematology and Clinical Immunology
Padova , 35128, Italy More Info
Site Contact
Contact
393488720396
[email protected]
Renato Zambello
Principal Investigator
Fondazione IRCCS Policlinico San Matteo
Pavia , 27100, Italy More Info
Site Contact
Contact
+39 0382503595
[email protected]
Silvia Mangiacavalli
Principal Investigator
Nagoya City University Hospital
Nagoya Aichi, 467-8, Japan More Info
Site Contact
Contact
+81528515511
[email protected]
Shinsuke Iida
Principal Investigator
Ogaki Municipal Hospital
Gifu-shi Gifu, 503-8, Japan More Info
Site Contact
Contact
+81 584-81-3341
[email protected]
Hiroshi Kosugi
Principal Investigator
University Hospital - Kyoto Preferctural University of Medicine
Kyoto-City Kyoto, 602-8, Japan More Info
Site Contact
Contact
+81752515740
[email protected]
Junya Kuroda
Principal Investigator
National Hospital Organization Okayama Medical Center
Okayama-city Okayama, 701-1, Japan More Info
Site Contact
Contact
+81862949911
[email protected]
Kazutaka Sunami
Principal Investigator
Yamanashi Prefectural Central Hospital
Chuo-shi Yamanasi, 409-3, Japan More Info
Site Contact
Contact
+81552537111
[email protected]
Masaki Iino
Principal Investigator
Japanese Red Cross Medical Center
Tokyo , 150-8, Japan More Info
Site Contact
Contact
+81 3-3400-1311
[email protected]
Tadao Ishida
Principal Investigator
Chonnam National University Hwasun Hospital
Hwasun Jeollanam-do, 58128, Korea, Republic of More Info
Site Contact
Contact
+82613797638
[email protected]
Je-Jung Lee
Principal Investigator
Seoul National University Hospital
Seoul , 03080, Korea, Republic of More Info
Site Contact
Contact
+82320723079
[email protected]
Sung-Soo Yoon
Principal Investigator
The Catholic University of Korea - Seoul St. Mary's Hospital
Seoul , 06591, Korea, Republic of More Info
Site Contact
Contact
+82222586053
[email protected]
Chang-Ki Min
Principal Investigator
Oslo Universitetssykehus-Ulleval Hospital
Oslo , 0450, Norway More Info
Site Contact
Contact
+4799697796
[email protected]
Fredrik Schjesvold
Principal Investigator
Ad-Vance Medical Research
Ponce , 00730, Puerto Rico More Info
Site Contact
Contact
7872597807
[email protected]
Hector Velez Cortes
Principal Investigator
Hospital Espanol Auxilio Mutuo
San Juan , 00919, Puerto Rico More Info
Site Contact
Contact
78775820003503
[email protected]
Fernando Cabanillas Escalona
Principal Investigator
Hospital Universitari Germans Trias i Pujol
Badalona Barcelona, 08916, Spain More Info
Site Contact
Contact
+34934978987
[email protected]
Albert Oriol Rocafiguera
Principal Investigator
Hospital Universitari Vall d'Hebron
Barcelona , 08035, Spain More Info
Site Contact
Contact
+34934893000
[email protected]
Mercedes Gironella Mesa
Principal Investigator
Hospital Clinic de Barcelona
Barcelona , 08036, Spain More Info
Site Contact
Contact
+34932275707
[email protected]
Laura Rosinol Dachs
Principal Investigator
Hospital Universitario 12 de Octubre
Madrid , 28041, Spain More Info
Site Contact
Contact
+34913908570
[email protected]
Rafael Alonso Fernandez
Principal Investigator
Hospital Universitario Virgen de la Arrixaca
Murcia , 30120, Spain More Info
Site Contact
Contact
34968369532
[email protected]
Maria Jose Moreno Belmonte
Principal Investigator
Hospital Universitario de Salamanca
Salamanca , 37007, Spain More Info
Site Contact
Contact
+34923291316
[email protected]
Maria Victoria Mateos Manteca
Principal Investigator
Hospital Universitario Marques de Valdecilla
Santander , 39008, Spain More Info
Site Contact
Contact
+34608429141
[email protected]
Enrique Ocio San Miguel
Principal Investigator
Tri-Service General Hospital
Taipei Taipei CITY, 11490, Taiwan More Info
Site Contact
Contact
+886287927208
[email protected]
Ming-Shen Dai
Principal Investigator
National Taiwan University Hospital
Taipei , 100, Taiwan More Info
Shang-Yi Huang
Principal Investigator
Taipei Veterans General Hospital
Taipei , 11217, Taiwan More Info
Po-Shen Ko
Principal Investigator
Ankara Universitesi
Yenimahalle Ankara, 06560, Turkey More Info
Site Contact
Contact
+904445946
[email protected]
Meral Beksac
Principal Investigator
Marmara Universitesi Pendik Egitim ve Arastirma Hastanesi
Üsküdar Istanbul, 34664, Turkey More Info
Site Contact
Contact
+9002166510000
[email protected]
Tulin Tuglular
Principal Investigator
Ondokuz Mayis Universitesi Tp Fakultesi
Samsun , 55139, Turkey More Info
Site Contact
Contact
+905324412859
[email protected]
Mehmet Turgut
Principal Investigator
University Hospitals Birmingham NHS Foundation Trust
Birmingham England, B9 5S, United Kingdom More Info
Site Contact
Contact
+4401214243699
[email protected]
Bhuvan Kishore
Principal Investigator
The Leeds Teaching Hospitals NHS Trust
Leeds England, LS9 7, United Kingdom More Info
Site Contact
Contact
+441132693939
[email protected]
Gordon Cook
Principal Investigator
University College London Hospitals NHS Foundation Trust
London England, NW1 2, United Kingdom More Info
Site Contact
Contact
+448451555000
[email protected]
Rakesh Popat
Principal Investigator
King's College Hospital NHS Foundation Trust
London England, SE5 9, United Kingdom More Info
Site Contact
Contact
+4402032999000
[email protected]
Reuben Benjamin
Principal Investigator
The Christie - The Christie NHS Foundation Trust
Manchester England, M20 4, United Kingdom More Info
Site Contact
Contact
01619187224
[email protected]
Emma Searle
Principal Investigator
Nottingham University Hospitals NHS Trust
Nottingham England, NG5 1, United Kingdom More Info
Yan Hodgson
Principal Investigator
Oxford University Hospitals NHS Foundation Trust
Oxford England, OX3 7, United Kingdom More Info
Site Contact
Contact
+4401865235882
[email protected]
Karthik Ramasamy
Principal Investigator
The Royal Marsden NHS Foundation Trust
Sutton England, SM2 5, United Kingdom More Info
Site Contact
Contact
+442087224130
[email protected]
Martin Kaiser
Principal Investigator
Genesis Care Windsor - Genesis Care UK Ltd.
Windsor England, SL43H, United Kingdom More Info
Site Contact
Contact
07989474250
[email protected]
Jaimal Kothari
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

336

Study ID:

NCT03215030

Recruitment Status:

Recruiting

Sponsor:


Takeda

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.